Overview

AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

Status:
Terminated
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH.
Phase:
Phase 3
Details
Lead Sponsor:
Tobira Therapeutics, Inc.
Treatments:
Cenicriviroc
TAK-652